ホームページへ

海外の子宮がん化学療法のベスト医師 — ページ2

コンテンツはBookimed編集ポリシーを満たし、以下により医学的にレビューされています

Fahad Mawlood

Cemil Bilir

  • 5 優秀 • 1 レビュー
  • 21年の経験
  • トルコ, イスタンブール, VM Medical Park Pendik Hospital
  • ジェミル・ビリール教授は医療腫瘍学を専門とし、VMメディカルパーク・ペンディク病院にて子宮がん治療の広範なトレーニングを受けています。

    • _doctor_9620_年_の医療腫瘍学における経験
    • クリーブランド・クリニックやノースイースタン大学など、権威ある機関で研修
    • ASCO、ESMO、TTODの会員
    • レジェップ・タイップ・エルドアン大学の准教授
    • 現在、サカリヤ大学にて無機化学の博士号(Ph.D.)を取得中
  • 続きを読む
診察
お問い合わせください
情報

Irfan Cicin

  • 5 優秀 • 1 レビュー
  • 29年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • トラキア大学医学部腫瘍内科教授 – 子宮がんの複雑な症例の治療を専門とする。

    • 腫瘍内科における_doctor_10980_年以上の経験
    • トラキア大学にて腫瘍内科のフェローシップ研修修了
    • 名門機関での在職中、広範な研究および学術的貢献
  • 続きを読む
診察
お問い合わせください
情報

Muhammed Mustafa Atci

  • 5 優秀 • 1 レビュー
  • 15年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • İstinye University Liv Hospital Topkapıの腫瘍内科准教授。子宮がん治療を専門とし、広範な研究実績を持つ。

    • 腫瘍内科における_doctor_10979_年以上の経験
    • 様々な癌治療に関する19本以上の査読付き論文を発表
    • 米国臨床腫瘍学会(ASCO)会員
    • 腫瘍内科部門の教育コーディネーター
  • 続きを読む
診察
お問い合わせください
情報

Ercan Ozden

  • 5 優秀 • 1 レビュー
  • 27年の経験
  • トルコ, イスタンブール, VM Medical Park Pendik Hospital
  • オズデン医師は腫瘍内科を専門としており、イスタンブール大学ジェラフパシャ医学部で広範なトレーニングを受けています。

    • コジャエリ大学にて腫瘍内科のサブスペシャリティを修了
    • 内科および腫瘍学において27 年以上の経験
    • シュルナク州立病院を含む複数の病院で勤務経験あり
  • 続きを読む
診察
お問い合わせください
情報

Mariam Mohammed Hussein Abu Zeid

  • 17年の経験
  • エジプト, カイロ, シファ・アル・オルマン国際腫瘍病院
  • マリアム・アブ・ザイド医師は、Shefaa Al Orman国際腫瘍病院の臨床腫瘍医です。欧州臨床腫瘍学会(ESMO)の認定を受けています。アブ・ザイド医師は、固形腫瘍および血液がんの治療を専門としています。アイン・シャムス大学で臨床腫瘍学および核医学の博士号(Ph.D.)を取得しています。

    • さまざまな種類のがんに対する化学療法、免疫療法、分子標的治療を実施。
    • 腫瘍学の臨床試験を監督し、治療に関連する毒性を管理。
    • 複雑な病期分類や診断のために、多職種チーム内で患者ケアを調整。
    • 年間約6,000人の患者を治療するESMO認定センターで勤務。
  • 続きを読む
診察
お問い合わせください
情報

Mustafa Serkan Alemdar

  • 4.6 優秀 • 7 レビュー
  • 20年の経験
  • トルコ, アンタルヤ, Medical Park Antalya Hospital Complex
  • アレムダル医師は腫瘍内科を専門としており、トルコ有数の医学部であるアクデニズ大学で研修を受けました。

    • 2018年より腫瘍内科の専門医認定を取得
    • メディカル・パーク・アンタルヤ病院複合施設にて勤務
    • 子宮がんの化学療法プロトコルにおける豊富な経験
    • イノニュ大学医学部での元教員
  • 続きを読む
診察
お問い合わせください
情報

Emad Shash

  • 20年の経験
  • エジプト, カイロ, シファ・アル・オルマン国際腫瘍病院
  • エマド・シャシュ医師は、70件以上の腫瘍学臨床試験に参加した腫瘍内科医です。NCIの乳がん総合病院で医療ディレクターを務めています。シャシュ医師は、化学療法、分子標的療法、免疫療法を含む全身療法を専門としています。JCIの病院品質管理および患者安全に関するディプロマを保持しています。

    • ESMOパネルの投票権を持つメンバーであり、ASCO委員会のメンバーでもあります。
    • 乳がん、婦人科がん、泌尿生殖器がん、胸部がん、消化器がん、および希少がんを治療しています。
    • ブリュッセルのEORTCで元研究医師および医療リーダーを務めました。
    • 年間6,000人の患者を治療するESMO認定腫瘍学センター、Shefaa Al Ormanで勤務しています。
  • 続きを読む
診察
お問い合わせください
情報

Maha Yahia

  • 21年の経験
  • エジプト, カイロ, シファ・アル・オルマン国際腫瘍病院
  • マハ・ヤヒア博士は、シェファ・アル・オルマン国際腫瘍病院の腫瘍内科医兼血液内科医です。エジプト軍医療隊で中佐の医師として勤務した経験があります。ヤヒア博士は、乳がん、胸部がん、消化器がんの治療計画を専門としています。免疫療法、分子標的療法、複雑な化学療法プロトコルに注力しています。

    • マーディ軍事医療センター(Maadi AFMC)の臨床研究支援チームの元リーダー。
    • カイロ大学国立がん研究所で血液腫瘍学の研修を修了。
    • 泌尿器がん、婦人科がん、希少がん、および血液疾患の治療を行う。
    • 年間6,000人の患者を治療するESMO認定センターに勤務。
  • 続きを読む
診察
お問い合わせください
情報

Zhang Jinshan

  • 41年の経験
  • 50000+件の治療実績
  • 中国, 成都, uni-asia hospital
  • Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

    1980–1985: Completed doctoral studies at Nagasaki University, Japan

    1968–present: Department of Radiology, Chinese PLA General Hospital

    1988: Third Prize of the Military Science and Technology Progress Award

    1989–present: Member of Radiological Society of North America(RSNA)

    1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

    1991: Second Prize of the Military Science and Technology Progress Award

    1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

    1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

    1993: Granted the Lifetime Special Government Allowance of the State Council

    1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

    1994: Third Prize of the Military Science and Technology Progress Award

    1997: Second Prize of the Military Science and Technology Progress Award

    1997–2009: Standing Member of Chinese Society of Radiology

    1999: Third Prize of the Military Science and Technology Progress Award

    1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

    2002: Second Prize of the Military Science and Technology Progress Award

    2005: Third Prize of the Military Science and Technology Progress Award

    Member of Radiological Society of North America(RSNA)

    Standing Member of Chinese Society of Radiology

    Group Leader of the Group of Intervention of Chinese Journal of Radiology

    Deputy Director Member of Chinese Society of Interventional Oncology

    Director Member of Beijing Medical Association Society of Interventional Radiology

    Deputy Chief Editor of Chinese Journal of Medical Image Technology

    Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

    Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

    Awarded the Special Government Allowance of the State Council

    Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

    Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

    Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

    In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

    zhang-jin-shan

    Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

    zhang-jin-shan

    In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

    zhang-jin-shan

    Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

    zhang-jin-shan

    From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

    Professor Zhang Jinshan’s Academic Achievements

    Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

    Selected Publications by Professor Zhang Jinshan

    1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993,27(6):361-365.

    Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

    2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996,30(8):521-524.

    Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

    3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998,14(3):189-191.

    Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

    4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000,34(5):335-337.

    Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

    5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002,36(7):612-614.

    Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

    6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004,20(9):1395-1397.

    Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

    7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006,40(8):876-878.

    Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

    8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008,28(10):856-858.

    Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

    Professor Zhang Jinshan co-authored monographs

    1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

    2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

    3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

    Professor Zhang Jinshan’s Research project

    1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

    2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

    3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

    4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

  • 続きを読む
診察
お問い合わせください
情報

Atakan Topcu

  • 5 優秀 • 3 レビュー
  • 13年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Atakan Topcu准教授は、Medipol Acibadem District病院にて、分子標的療法と免疫療法を中心とした腫瘍内科を専門としています。

    • 腫瘍学に関する50本以上の科学論文を発表
    • 老年腫瘍学およびがん関連の栄養不良の専門家
    • 欧州臨床腫瘍学会(ESMO)会員
    • Bezmialem Vakıf大学にてフェローシップ研修修了
  • 続きを読む
診察
お問い合わせください
情報

Ayse Irem Yasin

  • 5 優秀 • 3 レビュー
  • 15年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • 准教授のアイシェ・イレム・ヤシンは婦人科がんを専門とし、メディポール・アジバデム地区病院での経験を活かしています。

    • ベズミアレム・ヴァキフ大学にて腫瘍内科のフェローシップ修了
    • ESMO(欧州臨床腫瘍学会)認定医 – 腫瘍学における卓越性が認められています
    • ピエモンテ・オリエンターレ大学乳がんユニットでの国際研修
    • 婦人科悪性腫瘍の中でも子宮がんの治療に積極的に取り組んでいます
  • 続きを読む
診察
お問い合わせください
情報

Nail Paksoy

  • 4.5 良い • 2 レビュー
  • 15年の経験
  • 認定:
  • トルコ, イスタンブール, Medipol Bahçelievler Hospital
  • 准教授のネイル・パクソイは、メディポル・バフチェリエヴレル病院にて子宮がんの化学療法を専門としており、特に進行性子宮内膜がんの治療に注力しています。

    • ESMO(欧州臨床腫瘍学会)認定医(医療腫瘍学)
    • 再発子宮内膜がんを対象としたRUBY試験のサブインベスティゲーター
    • 婦人科がんの化学療法プロトコルに関する研究論文を発表
    • イスタンブール大学腫瘍学研究所にてフェローシップ修了
  • 続きを読む
診察
お問い合わせください
情報

Ahmer Arif Shaikh

  • 15年の経験
  • インド, ナーシク, HCG Manavata Cancer Centre
  • アーマー・アリフ・シェイク医師は、HCGマナヴァタがんセンターにて、口腔がんおよび機能リハビリテーションに重点を置いた外科腫瘍学を専門としています。

    • 15 年 の外科腫瘍学における経験
    • 臓器温存および機能リハビリテーションにおける専門知識
    • 主要な顎顔面および頭頸部手術に精通
    • 頭頸部外科腫瘍学のフェローシップ研修修了
    • 多数の論文を発表している研究者
  • 続きを読む
診察
お問い合わせください
情報

Sridhar P.S.

  • 30年の経験
  • インド, ナーシク, HCG Manavata Cancer Centre
  • スリダール・P.S.医師は放射線治療を専門とし、30 年以上の経験を持ち、HCGマナヴァタがんセンターで子宮がん治療に注力しています。

    • バナラス・ヒンドゥー大学で訓練を受け、放射線治療の国家資格(Diplomate of National Board)を保持
    • インド放射線腫瘍学会およびバンガロール腫瘍学グループのメンバー
    • 子宮がんに対する高度な化学療法および放射線治療技術を専門とする
  • 続きを読む
診察
お問い合わせください
情報

Shruti Kate

  • 15年の経験
  • インド, ナーシク, HCG Manavata Cancer Centre
  • シュルティ・ケイト医師は婦人科がんを専門とし、免疫療法とメトロノーム療法において深い専門知識を有しています。インド有数の癌センターであるタタ記念病院で研修を受けました。

    • タタ記念病院にて医療腫瘍学のDM(博士号)を取得
    • ASCO、ESMOおよびその他の主要な腫瘍学会の会員
    • 世界肺癌会議にて肺がん研究を発表
    • 子宮がんを含むすべての固形腫瘍を治療
  • 続きを読む
診察
お問い合わせください
情報

Muhammed Gomec

  • 5 優秀 • 1 レビュー
  • 17年の経験
  • トルコ, スィヴァス, Medicana Sivas Hospital
診察
お問い合わせください
情報

Gul Alco

  • 4.5 良い • 495 レビュー
  • 23年の経験
  • トルコ, イスタンブール, Medipol Mega University Hospital
  • Gül Alço教授は、約27年の経験を持つ放射線腫瘍医です。乳がん、肺がん、前立腺がん、消化器がん、婦人科がん、中枢神経系腫瘍、頭頸部がん、軟部組織腫瘍、骨腫瘍の放射線治療を行っています。

    専門分野は、適応放射線治療とラジオサージャリー(放射線外科)です。高度な放射線技術を駆使し、患者中心の多職種連携環境において、個別化された科学的根拠に基づくケアを提供しています。

  • 続きを読む
診察
お問い合わせください
情報

Ma Xiao Ying

  • 4.6 優秀 • 0 レビュー
  • 22年の経験
  • マレーシア, クラン, St. Stamford Modern Cancer Hospital Guangzhou
診察
お問い合わせください
情報

Dai Wen Yan

  • 4.6 優秀 • 0 レビュー
  • 21年の経験
  • マレーシア, クラン, St. Stamford Modern Cancer Hospital Guangzhou
診察
お問い合わせください
情報